United Therapeutics (UTHR) News Today $359.58 -0.58 (-0.16%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period United Therapeutics (NASDAQ:UTHR) Downgraded to "Buy" Rating by StockNews.comDecember 21 at 3:17 AM | americanbankingnews.comUnited Therapeutics (NASDAQ:UTHR) Stock Rating Lowered by StockNews.comStockNews.com cut shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Thursday.December 19 at 11:14 PM | marketbeat.comInsider Sell: Louis Sullivan Sells 26,209 Shares of United Therapeutics CorpDecember 19 at 7:30 PM | gurufocus.comUnited Therapeutics Co. (NASDAQ:UTHR) Director Sells $9,781,722.98 in StockUnited Therapeutics Co. (NASDAQ:UTHR - Get Free Report) Director Louis W. Sullivan sold 26,209 shares of the stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $373.22, for a total value of $9,781,722.98. Following the sale, the director now directly owns 5,051 shares of the company's stock, valued at approximately $1,885,134.22. This represents a 83.84 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.December 19 at 7:22 PM | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) Trading Down 4.4% - Here's WhyUnited Therapeutics (NASDAQ:UTHR) Stock Price Down 4.4% - Here's What HappenedDecember 18 at 5:12 PM | marketbeat.comCautious Hold: United Therapeutics’ Promising UKidney Progress Amidst Regulatory HurdlesDecember 18 at 2:44 AM | markets.businessinsider.comUnited Therapeutics President Michael Benkowitz sells $3.7M in sharesDecember 17, 2024 | markets.businessinsider.comUnited Therapeutics Announces Successful World’s First UKidney TransplantDecember 17, 2024 | finance.yahoo.comWho wants a pig organ? Patients sick and tired of waiting years for a transplantPeople worried they'll never get a scarce human transplant want to know when they might get a pig kidney insteadDecember 17, 2024 | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Shares Bought by Franklin Resources Inc.Franklin Resources Inc. boosted its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 97.7% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 250,719 shares of the biotechnology company's stockDecember 16, 2024 | marketbeat.comLord Abbett & CO. LLC Buys 46,170 Shares of United Therapeutics Co. (NASDAQ:UTHR)Lord Abbett & CO. LLC raised its stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 29.7% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 201,695 shares of the biotechnology coDecember 15, 2024 | marketbeat.comTidal Investments LLC Purchases 2,803 Shares of United Therapeutics Co. (NASDAQ:UTHR)Tidal Investments LLC lifted its position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 33.1% in the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 11,272 shares of the biotechnology company's stock after acquiring an additional 2,80December 15, 2024 | marketbeat.comBarclays PLC Sells 15,445 Shares of United Therapeutics Co. (NASDAQ:UTHR)Barclays PLC trimmed its position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 20.9% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 58,594 shares of the biotechnology company's stock after selling 15,445 shares during the period. BarclDecember 15, 2024 | marketbeat.comOddo BHF Asset Management Sas Invests $1.70 Million in United Therapeutics Co. (NASDAQ:UTHR)Oddo BHF Asset Management Sas bought a new stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 4,738 shares of the biotechnology company's stoDecember 14, 2024 | marketbeat.comGeode Capital Management LLC Purchases 45,566 Shares of United Therapeutics Co. (NASDAQ:UTHR)Geode Capital Management LLC increased its position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 4.3% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,094,015 shares of the biotechnology company's stDecember 14, 2024 | marketbeat.comRetirement Systems of Alabama Sells 12,481 Shares of United Therapeutics Co. (NASDAQ:UTHR)Retirement Systems of Alabama trimmed its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 8.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 129,372 shares of the biotechnology company's stocDecember 13, 2024 | marketbeat.com21,448 Shares in United Therapeutics Co. (NASDAQ:UTHR) Acquired by Tri Ri Asset Management CorpTri Ri Asset Management Corp purchased a new position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 21,448 shares of the biotechnology company's stock, valued at approximately $7,686,000December 13, 2024 | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Stock Holdings Lessened by Nomura Asset Management Co. Ltd.Nomura Asset Management Co. Ltd. cut its stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 10.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 25,637 shares of the bDecember 12, 2024 | marketbeat.comEP Wealth Advisors LLC Invests $576,000 in United Therapeutics Co. (NASDAQ:UTHR)EP Wealth Advisors LLC bought a new stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) during the 3rd quarter, according to its most recent filing with the SEC. The fund bought 1,608 shares of the biotechnology company's stock, valued at approximately $576,000. A number of otherDecember 12, 2024 | marketbeat.com$1000 Invested In United Therapeutics 20 Years Ago Would Be Worth This Much TodayDecember 11, 2024 | benzinga.comUnited Therapeutics Co. (NASDAQ:UTHR) Shares Sold by iA Global Asset Management Inc.iA Global Asset Management Inc. reduced its stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 64.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 981 shares of tDecember 11, 2024 | marketbeat.comBrophy Wealth Management LLC Acquires New Stake in United Therapeutics Co. (NASDAQ:UTHR)Brophy Wealth Management LLC bought a new position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 2,258 shares of the biotechnology company's stock, valued atDecember 10, 2024 | marketbeat.comWorldquant Millennium Advisors LLC Sells 34,562 Shares of United Therapeutics Co. (NASDAQ:UTHR)Worldquant Millennium Advisors LLC lessened its stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 81.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,688 shares of the biotechnology company's sDecember 9, 2024 | marketbeat.com5,769 Shares in United Therapeutics Co. (NASDAQ:UTHR) Bought by Dorsey Wright & AssociatesDorsey Wright & Associates purchased a new position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 5,769 shares of the biotechnology company's stock, valuedDecember 8, 2024 | marketbeat.comMain Management ETF Advisors LLC Purchases Shares of 2,328 United Therapeutics Co. (NASDAQ:UTHR)Main Management ETF Advisors LLC purchased a new stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 2,328 shares of the biotechnology company's stock, valued at approximately $834,0December 8, 2024 | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Position Cut by State Street CorpState Street Corp lowered its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 2.4% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,238,224 shares of the biotechnologyDecember 8, 2024 | marketbeat.comInsider Selling: United Therapeutics Co. (NASDAQ:UTHR) EVP Sells 7,700 Shares of StockDecember 7, 2024 | insidertrades.comUnited Therapeutics Co. (NASDAQ:UTHR) EVP Sells $2,882,649.00 in StockUnited Therapeutics Co. (NASDAQ:UTHR - Get Free Report) EVP Paul A. Mahon sold 7,700 shares of United Therapeutics stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $374.37, for a total value of $2,882,649.00. Following the completion of the transaction, the executive vice president now owns 36,710 shares in the company, valued at approximately $13,743,122.70. The trade was a 17.34 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.December 6, 2024 | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Shares Acquired by Chevy Chase Trust Holdings LLCChevy Chase Trust Holdings LLC increased its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 106.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 23,049 shares of the biotechnology coDecember 6, 2024 | marketbeat.comUnited Therapeutics management to meet with OppenheimerDecember 6, 2024 | markets.businessinsider.comJanus Henderson Group PLC Acquires 50,409 Shares of United Therapeutics Co. (NASDAQ:UTHR)Janus Henderson Group PLC grew its position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 12.3% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 460,419 shares of the biotechnology company's stock after buying an additionaDecember 5, 2024 | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Shares Sold by BRITISH COLUMBIA INVESTMENT MANAGEMENT CorpBRITISH COLUMBIA INVESTMENT MANAGEMENT Corp trimmed its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 17.9% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 7,034 shares of the biotechnologyDecember 5, 2024 | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Given Average Rating of "Moderate Buy" by BrokeragesShares of United Therapeutics Co. (NASDAQ:UTHR - Get Free Report) have earned an average recommendation of "Moderate Buy" from the fifteen research firms that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have assDecember 5, 2024 | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Parkman Healthcare Partners LLCParkman Healthcare Partners LLC trimmed its position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 42.5% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 64,031 shares of the biotechnology company's stock after sellingDecember 4, 2024 | marketbeat.comEdgestream Partners L.P. Buys New Position in United Therapeutics Co. (NASDAQ:UTHR)Edgestream Partners L.P. purchased a new position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 4,421 shares of the biotechnology company's stock, valued at approximately $December 4, 2024 | marketbeat.comPDT Partners LLC Sells 5,560 Shares of United Therapeutics Co. (NASDAQ:UTHR)PDT Partners LLC decreased its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 85.0% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 980 shares of the biotechnology company's stock after seDecember 4, 2024 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $76.21 Million Holdings in United Therapeutics Co. (NASDAQ:UTHR)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 12.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 21December 3, 2024 | marketbeat.comErste Asset Management GmbH Acquires New Stake in United Therapeutics Co. (NASDAQ:UTHR)Erste Asset Management GmbH acquired a new position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 45,266 shares of the biotechnology company's stock,December 2, 2024 | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Stake Trimmed by Zurcher Kantonalbank Zurich CantonalbankZurcher Kantonalbank Zurich Cantonalbank cut its position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 14.2% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 29,123 shares of the bioteDecember 2, 2024 | marketbeat.comBNP Paribas Financial Markets Has $12.25 Million Stake in United Therapeutics Co. (NASDAQ:UTHR)BNP Paribas Financial Markets lessened its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 38.5% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 34,192 shares of the biotechnology company's sDecember 2, 2024 | marketbeat.comTrue Wealth Design LLC Reduces Position in United Therapeutics Co. (NASDAQ:UTHR)True Wealth Design LLC trimmed its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 95.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 169 shares of the biotechnology company's stock after selling 3,274 shares durDecember 1, 2024 | marketbeat.comFmr LLC Has $386.17 Million Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)Fmr LLC lifted its stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 41.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,077,628 shares of the biotechnology company's stockDecember 1, 2024 | marketbeat.comBank of Montreal Can Decreases Stake in United Therapeutics Co. (NASDAQ:UTHR)Bank of Montreal Can decreased its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 11.5% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 38,013 shares of the biotechnology company's stock after sDecember 1, 2024 | marketbeat.comCerity Partners LLC Buys 4,005 Shares of United Therapeutics Co. (NASDAQ:UTHR)Cerity Partners LLC grew its stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 82.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,886 shares of the biotechnology comDecember 1, 2024 | marketbeat.comMartingale Asset Management L P Sells 5,664 Shares of United Therapeutics Co. (NASDAQ:UTHR)Martingale Asset Management L P trimmed its position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 13.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 37,102 shares of the biotechnology company'November 30, 2024 | marketbeat.comCrawford Fund Management LLC Has $8.49 Million Stock Position in United Therapeutics Co. (NASDAQ:UTHR)Crawford Fund Management LLC decreased its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 29.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 23,692 shares of the biotechnoNovember 29, 2024 | marketbeat.comThe 3.8% return this week takes United Therapeutics' (NASDAQ:UTHR) shareholders five-year gains to 314%November 29, 2024 | finance.yahoo.comGlenmede Trust Co. NA Purchases 4,145 Shares of United Therapeutics Co. (NASDAQ:UTHR)Glenmede Trust Co. NA raised its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 6.4% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 68,605 shares of the biotechnology company's stNovember 28, 2024 | marketbeat.comBridgewater Associates LP Raises Position in United Therapeutics Co. (NASDAQ:UTHR)Bridgewater Associates LP lifted its stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 384.3% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 61,755 shares of the biotechnology company's stockNovember 28, 2024 | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) COO Michael Benkowitz Sells 10,000 SharesUnited Therapeutics Co. (NASDAQ:UTHR - Get Free Report) COO Michael Benkowitz sold 10,000 shares of the stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $372.75, for a total transaction of $3,727,500.00. Following the sale, the chief operating officer now directly owns 2,577 shares in the company, valued at $960,576.75. This represents a 79.51 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.November 27, 2024 | marketbeat.com Get United Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter. Email Address We recommended Palantir in 2021, now we’re recommending this... (Ad)My research indicates there is only one investment that can meet AI's unprecedented demand for energy. Click to get the name and ticker symbol UTHR Media Mentions By Week UTHR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. UTHR News Sentiment▼1.070.61▲Average Medical News Sentiment UTHR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. UTHR Articles This Week▼1410▲UTHR Articles Average Week Get United Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ALNY News BIIB News NBIX News INCY News BMRN News EXAS News EXEL News RGEN News MDGL News HALO News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:UTHR) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding United Therapeutics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share United Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free UTHR Stock Alerts